No Data
Zhejiang Shapuaisi PharmaceuticalLtd (SHSE:603168) Adds CN¥380m to Market Cap in the Past 7 Days, Though Investors From a Year Ago Are Still Down 22%
Zhejiang Shapuaisi Pharmaceutical (603168.SH): The first subject has been enrolled in the Phase III clinical trial of Azithromycin eye drops.
On March 11, Gelonghui reported that Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced the completion of the first subject enrollment for the Phase III clinical trial of Azithromycin Eye Drops organized by the company. The Phase III clinical trial of Azithromycin Eye Drops is designed as a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Azithromycin Eye Drops in patients with purulent bacterial conjunctivitis in China, with the first subject enrollment completed on March 10, 2025.
Zhejiang Shapuaisi Pharmaceutical Gets NMPA's Nod for Olopatadine Eye Drops
Zhejiang Shapuaisi Pharmaceutical (603168.SH): Shanghai Jingxing has collectively reduced their shareholding by 1.6619 million shares, with the reduction period now expired.
Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that Shanghai Jingxing plans to reduce its shareholding on November 22, 2024...
Zhejiang Shapuaisi Pharmaceutical (603168.SH): has obtained the Pharmaceutical registration certificate for sodium bromfenac eye drops.
On January 21, Gelonghui announced that Zhejiang Shapuaisi Pharmaceutical (603168.SH) has received the drug registration certificate for sodium bromfenac eye drops approved and issued by the National Medical Products Administration. The approved sodium bromfenac eye drops are intended for symptomatic treatment of inflammatory diseases in the external eye and anterior segment: blepharitis, conjunctivitis, scleritis (including superficial scleritis), and postoperative inflammation.
Sharp Ace 2024 Annual Results Pre-loss Announcement
What Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s (SHSE:603168) 27% Share Price Gain Is Not Telling You
